Skip to main content
Premium Trial:

Request an Annual Quote

... As Genospectra Plans to Acquire Reagents Shop Panomics

NEW YORK, Feb. 10 (GenomeWeb News) - Genospectra will acquire Panomics, a provider of research reagents for transcription regulation, cell signaling, and signal transduction, the companies said today

 

In conjunction with the acquisition, and disclosed separately today, Genospectra closed a $12.2-million financing with Sigma-Aldrich and certain existing investors and affiliates of both companies.

 

Panomics, which is located in Redwood City, Calif., sells multiplex assays for the global analysis of transcriptional regulation and cell signaling. "By combining this portfolio with Genospectra's ... products and technologies for Parallel Quantitative Biology, the new company will provide an integrated pipeline of products in the functional biology and drug discovery space," Genospectra said in a statement.

 

The combined company, which will be called Panomics, will play in markets including cell signaling, RNAi-mediated gene silencing and high performance assays, clinical biomarker discovery, and predictive toxicology.

 

Genospectra CEO Frank Witney will be CEO of the new company and Jason Li, founder and CEO of Panomics, will be chief operating officer.

 

The new company will be headquartered at Genospectra's existing facilities in Fremont, Calif.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.